Courtney DiNardo, MD, on Next Steps in Combination Regimens to Treat IDH1-Positive AML

The MD Anderson Cancer Center expert discussed next steps in the evaluation of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.

Researchers are no finishing phase 1 of a trial designed to evaluate ivosenidib (Tibsovo) plus venetoclax (Venclexta) with or without azacytidine (Vidaza) in patients with IDH1-mutated acute myeloid leukemia (AML).

As part of a phase Ib/II trial, presented at the 2020 ASCO Virtual Scientific Program, the triplet appeared to be effective. As a next step, in phase 2 of the trial, the researchers will evaluate the regimen in treatment-naïve patients and those with relapsed/refractory IDH1-mutated AML.

In an interview with CancerNetwork, senior study author Courtney DiNardo, MD, associate professor of leukemia at The University of Texas MD Anderson Cancer Center, discussed next steps for the trial.


We are finishing up the phase 1 portion, which is where we're going to finish dosing the 2 different triplet cohorts. And then what we're going to do is take a step back and kind of analyze all the data figure out in which cohorts we saw the best responses and the most durable responses, the deepest remissions. And then we're going to move into the phase 2 portion, which is where we're going to take 2 different groups, the treatment-naive and the relapsed/refractory patients and kind of build out like a 20-patient cohort each, so 40 patients in the phase 2 to get a better sense of efficacy in these different subgroups and figure if it could actually be different treatments in those 2 different cohorts.

We may decide for 1 that the doublet is the right thing to do in the triplet and just build upon the responses and, in particular, the duration of remission. That point I think is going to be really important.

Related Videos
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.
C. Ola Landgren, MD, PhD, discusses progression-free survival findings from the phase 3 DETERMINATION trial, examining lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Paul G. Richardson, MD, Highlights Benefits of Continuous Lenalidomide Maintenance Vs ASCT in Newly Diagnosed Myeloma